Benitec Biopharma: ASX Investor Series (Syd, Oct 2014)

Company Presentations

Benitec Biopharma Limited (ASX:BLT)Chief Business Officer Carl Stubbingspresents at the ASX Investor Series in Sydney.  
The biotechnology company working on gene silencing therapies for a range of debilitating illnesses and its treatments for HIV has been approved for stage 2 trials in the US.
Mr Stubbings’ presentation is titled, “Gene Silencing: A quiet revolution in healthcare” and covers the company’s investment case, value proposition and recent highlights.